Structure Therapeutics (GPCR) Total Non-Current Liabilities (2022 - 2026)

Structure Therapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $60.2 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 44.62% year-over-year to $60.2 million; the TTM figure through Mar 2026 stood at $60.2 million (up 44.62% YoY), while the FY2025 annual figure was $66.9 million, up 75.18% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $60.2 million, down from $66.9 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $66.9 million in Q4 2025, with the low at $13.0 million in Q4 2022.
• The 5-year median for Total Non-Current Liabilities is $37.1 million (2024), against an average of $38.9 million.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 121.01% in 2023, then surged 32.8% in 2024.
• Structure Therapeutics' Total Non-Current Liabilities stood at $13.0 million in 2022, then surged by 121.01% to $28.8 million in 2023, then jumped by 32.8% to $38.2 million in 2024, then soared by 75.18% to $66.9 million in 2025, then retreated by 10.06% to $60.2 million in 2026.
• Business Quant data shows GPCR's Total Non-Current Liabilities at $60.2 million in Q1 2026, $66.9 million in Q4 2025, and $61.8 million in Q3 2025.